Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
Source: SeekingAlpha
2026-02-23 16:25:10 ET
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension February 23, 2026 8:30 AM EST...
Read the full article on Seeking Alpha
For further details see:
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
Gossamer Bio Inc.
NASDAQ: GOSS
GOSS Trading
-8.61% G/L:
$0.4619 Last:
4,754,964 Volume:
$0.48 Open:
GOSS Latest News
March 01, 2026 04:07:00 pm
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
GOSS Stock Data
$545,079,462
180,998,785
0.97%
49
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
